A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.
J Immunol
; 205(4): 915-922, 2020 08 15.
Article
en En
| MEDLINE
| ID: mdl-32591393
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions of infections and hundreds of thousands of deaths globally. There are no widely available licensed therapeutics against SARS-CoV-2, highlighting an urgent need for effective interventions. The virus enters host cells through binding of a receptor-binding domain within its trimeric spike glycoprotein to human angiotensin-converting enzyme 2. In this article, we describe the generation and characterization of a panel of murine mAbs directed against the receptor-binding domain. One mAb, 2B04, neutralized wild-type SARS-CoV-2 in vitro with remarkable potency (half-maximal inhibitory concentration of <2 ng/ml). In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination. Thus, 2B04 is a promising candidate for an effective antiviral that can be used to prevent SARS-CoV-2 infection.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Infecciones por Coronavirus
/
Anticuerpos Neutralizantes
/
Betacoronavirus
/
Anticuerpos Monoclonales
/
Anticuerpos Antivirales
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
J Immunol
Año:
2020
Tipo del documento:
Article